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HYPOTHESIS SETTING AND ORDER STATISTIC FOR
ROBUST GENOMIC META-ANALYSIS1
By Chi Song and George C. Tseng
University of Pittsburgh
Meta-analysis techniques have been widely developed and applied
in genomic applications, especially for combining multiple transcrip-
tomic studies. In this paper we propose an order statistic of p-values
(rth ordered p-value, rOP) across combined studies as the test statis-
tic. We illustrate different hypothesis settings that detect gene mark-
ers differentially expressed (DE) “in all studies,” “in the majority
of studies” or “in one or more studies,” and specify rOP as a suit-
able method for detecting DE genes “in the majority of studies.”
We develop methods to estimate the parameter r in rOP for real
applications. Statistical properties such as its asymptotic behavior
and a one-sided testing correction for detecting markers of concor-
dant expression changes are explored. Power calculation and simula-
tion show better performance of rOP compared to classical Fisher’s
method, Stouffer’s method, minimum p-value method and maximum
p-value method under the focused hypothesis setting. Theoretically,
rOP is found connected to the na¨ıve vote counting method and can be
viewed as a generalized form of vote counting with better statistical
properties. The method is applied to three microarray meta-analysis
examples including major depressive disorder, brain cancer and dia-
betes. The results demonstrate rOP as a more generalizable, robust
and sensitive statistical framework to detect disease-related markers.
1. Introduction. With the advances in high-throughput experimental
technology in the past decade, the production of genomic data has become
affordable and thus prevalent in biomedical research. Accumulation of ex-
perimental data in the public domain has grown rapidly, particularly of
microarray data for gene expression analysis and single nucleotide polymor-
phism (SNP) genotyping data for genome-wide association studies (GWAS).
For example, the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.
nih.gov/geo/) from the National Center for Biotechnology Information
Received June 2012; revised July 2013.
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(NCBI) and the Gene Expression Atlas (http://www.ebi.ac.uk/gxa/) from
the European Bioinformatics Institute (EBI) are the two largest public de-
pository websites for gene expression data and the database of Genotypes
and Phenotypes (dbGaP, http://www.ncbi.nlm.nih.gov/gap/) has the
largest collection of genotype data. Because individual studies usually con-
tain limited numbers of samples and the reproducibility of genomic stud-
ies is relatively low, the generalizability of their conclusions is often crit-
icized. Therefore, combining multiple studies to improve statistical power
and to provide validated conclusions has emerged as a common practice
[see recent review papers by Tseng, Ghosh and Feingold (2012) and Begum
et al. (2012)]. Such genomic meta-analysis is particularly useful in microar-
ray analysis and GWAS. In this paper we focus on microarray meta-analysis
while the proposed methodology can be applied to the traditional “univari-
ate” meta-analysis or other types of genomic meta-analysis.
Microarray experiments measure transcriptional activities of thousands
of genes simultaneously. One commonly seen application of microarray data
is to detect differentially expressed (DE) genes in samples labeled with two
conditions (e.g., tumor recurrence versus nonrecurrence), multiple condi-
tions (e.g., multiple tumor subtypes), survival information or time series. In
the literature, microarray meta-analysis usually refers to combining multi-
ple studies of related hypotheses or conditions to better detect DE genes
(also called candidate biomarkers). For this problem, two major types of
statistical procedures have been used: combining effect sizes or combining
p-values. Generally speaking, no single method performs uniformly better
than the others in all data sets for various biological objectives, both from
a theoretical point of view [Littell and Folks (1971, 1973)] and from empir-
ical experiences. In combining effect sizes, the fixed effects model and the
random effects model are the most popular methods [Cooper, Hedges and
Valentine (2009)]. These methods are usually more straightforward and pow-
erful to directly synthesize information of the effect size estimates, compared
to p-value combination methods. They are, however, only applicable to sam-
ples with two conditions when the effect sizes can be defined and combined.
On the other hand, methods combining p-values provide better flexibility
for various outcome conditions as long as p-values can be assessed for inte-
gration. Fisher’s method is among the earliest p-value methods applied to
microarray meta-analysis [Rhodes et al. (2002)]. It sums the log-transformed
p-values to aggregate statistical significance across studies. Under the null
hypothesis, assuming that the studies are independent and the hypothesis
testing procedure correctly fits the observed data, Fisher’s statistic follows
a chi-squared distribution with degrees of freedom 2K, where K is the num-
ber of studies combined. Other methods such as Stouffer’s method [Stouffer
et al. (1949)], the minP method [Tippett (1931)] and the maxP method
[Wilkinson (1951)] have also been widely used in microarray meta-analysis.
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It can be shown that these test statistics have simple analytical forms of null
distributions and, thus, they are easy to apply to the genomic settings. The
assumptions and hypothesis settings behind these methods are, however,
very different and have not been carefully considered in most microarray
meta-analysis applications so far. In Fisher, Stouffer and minP, the methods
detect markers that are differentially expressed in “one or more” studies (see
the definition of HSB in Section 2.1). In other words, an extremely small p-
value in one study is usually enough to impact the meta-analysis and cause
statistical significance. On the contrary, methods like maxP tend to detect
markers that are differentially expressed in “all” studies (called HSA in Sec-
tion 2.1) since maxP requires that all combined p-values are small for a
marker to be detected. In this paper, we begin in Section 2.1 to elucidate
the hypothesis settings and biological implications behind these methods. In
many meta-analysis applications, detecting markers differentially expressed
in all studies is more appealing. The requirement of DE in “all” studies,
however, is too stringent when K is large and in light of the fact that ex-
perimental data are peppered with noisy measurements from probe design,
sample collection, data generation and analysis. Thus, we describe in Sec-
tion 2.1 a robust hypothesis setting (called HSr) that detects biomarkers
differentially expressed “in the majority of” studies (e.g., >70% of the stud-
ies) and we propose a robust order statistic, the rth ordered p-value (rOP),
for this hypothesis setting.
The remainder of this paper is structured as follows to develop the rOP
method. In Section 2.2 the rationale and algorithm of rOP are outlined,
and the methods for parameter estimation are described in Section 2.3.
Section 2.4 extends rOP with a one-sided test correction to avoid detection
of DE genes with discordant fold change directions across studies. Section 3
demonstrates applications of rOP to three examples in brain cancer, major
depressive disorder (MDD) and diabetes, and compares the result with other
classical meta-analysis methods. We further explore power calculation and
asymptotic properties of rOP in Section 4.1, and evaluate rOP in genomic
settings by simulation in Section 4.2. We also establish an unexpected but
insightful connection of rOP with the classical na¨ıve vote counting method
in Section 4.3. Section 5 contains final conclusions and discussions.
2. rth ordered p-value (rOP).
2.1. Hypothesis settings and motivation. We consider the situation when
K transcriptomic studies are combined for a meta-analysis where each study
contains G genes for information integration. Denote by θgk the underlying
true effect size for gene g and study k (1≤ g ≤G, 1≤ k ≤K). For a given
gene g, we follow the convention of Birnbaum (1954) and Li and Tseng
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(2011) to consider two complementary hypothesis settings, depending on
the pursuit of different types of targeted markers:
HSA :
{
H0 :
⋂
k
{θgk = 0} versus H
(A)
a :
⋂
k
{θgk 6= 0}
}
,
HSB :
{
H0 :
⋂
k
{θgk = 0} versus H
(B)
a :
⋃
k
{θgk 6= 0}
}
.
In HSA, the targeted biomarkers are those differentially expressed in all
studies (i.e., the alternative hypothesis is the intersection event that effect
sizes of all K studies are nonzero), while HSB pursues biomarkers differ-
entially expressed in one or more studies (the alternative hypothesis is the
union event instead of the intersection in HSA). Biologically speaking, HSA
is more stringent and more desirable to identify consistent biomarkers across
all studies if the studies are homogeneous. HSB , however, is useful when het-
erogeneity is expected. For example, if studies analyzing different tissues are
combined (e.g., study 1 uses epithelial tissues and study 2 uses blood sam-
ples), it is reasonable to identify tissue-specific biomarkers detected by HSB .
We note that HSB is identical to the classical union-intersection test (UIT)
[Roy (1953)] but HSA is different from the intersection-union test (IUT)
[Berger (1982), Berger and Hsu (1996)]. In IUT, the statistical hypothesis
is in a complementary form between the null and alternative hypotheses
{H0 :
⋃
k{θgk = 0} versus H
(A)
a :
⋂
k{θgk 6= 0}}. Solutions for IUT require a
more sophisticated mixture or Bayesian modeling to accommodate the com-
posite null hypothesis and are not the focus of this paper [for more details,
see Erickson, Kim and Allison (2009)].
As discussed in Tseng, Ghosh and Feingold (2012), most existing ge-
nomic meta-analysis methods target on HSB . Popular methods include clas-
sical Fisher’s method [sum of minus log-transformed p-values; Fisher (1925)],
Stouffer’s method [sum of inverse-normal-transformed p-values; Stouffer et al.
(1949)], minP [minimum of combined p-values; Tippett (1931)] and a re-
cently proposed adaptively weighted (AW) Fisher’s method [Li and Tseng
(2011)]. The random effects model targets on a slight variation of HSA,
where the effect sizes in the alternative hypothesis are random effects drawn
from a Gaussian distribution centered away from zero (but are not guaran-
teed to be all nonzero). The maximum p-value method (maxP) is probably
the only method available to specifically target on HSA so far. By tak-
ing the maximum of p-values from combined studies as the test statistic,
the method requires that all p-values be small for a gene to be detected.
Assuming independence across studies and that the inferences to gener-
ate p-values in single studies are correctly specified, p-values (pk as the
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p-value of study k) are i.i.d. uniformly distributed in [0,1]. Fisher’s statistic
(SFisher =−2
∑
log pk) follows a chi-squared distribution with degree of free-
dom 2K [i.e., SFisher ∼ χ2(2K)] under null hypothesis H0; Stouffer’s statistic
[SStouffer =
∑
Φ−1(1− pk), where Φ
−1(·) is the quantile function of a stan-
dard normal distribution] follows a normal distribution with variance K
[i.e., SStouffer ∼ N(0,K)]; minP statistic (SminP =min{pk}) follows a Beta
distribution with parameters 1 and K [i.e., SminP ∼ Beta(1,K)]; and maxP
statistic (SmaxP =max{pk}) follows a Beta distribution with parameters K
and 1 [i.e., SmaxP ∼ Beta(K,1)].
The HSA hypothesis setting and maxP method are obviously too stringent
in light of the generally noisy nature of microarray experiments. When K
is large, HSA is not robust and inevitably detects very few genes. Instead of
requiring differential expression in all studies, biologists are more interested
in, for example, “biomarkers that are differentially expressed in more than
70% of the combined studies.” Denote by Θh = {
∑K
k=1 I(θgk 6= 0) = h} the
situation that exactly h out of K studies are differentially expressed. The
new robust hypothesis setting becomes
HSr :
{
H0 :
⋂
k
{θgk = 0} versus H
(r)
a :
K⋃
h=r
Θh
}
,
where r = ⌈p ·K⌉, ⌈x⌉ is the smallest integer no less than x and p (0< p≤ 1)
is the minimal percentage of studies required to call differential expression
(e.g., p = 70%). We note that HSA and HSB are both special cases of the
extended HSr class (i.e., HSA =HSK and HSB =HS1), but we will focus on
large r (i.e., p > 50%) in this paper and view HSr as a relaxed and robust
form of HSA.
In the literature, maxP has been used for HSA and minP has been used
for HSB . An intuitive extension of these two methods for HSr is to use the
rth ordered p-value (rOP). Before introducing the algorithm and properties
of rOP, we illustrate the motivation of it by the following example. Suppose
we consider four genes in five studies: gene A has marginally significant p-
values (p = 0.1) in all five studies; gene B has a strong p-value in study
1 (p = 1e–20) but p = 0.9 in the other four studies; gene C is similar to
gene A but has much weaker statistical significance (p = 0.25 in all five
studies); gene D differs from gene C in that studies 1–4 have small p-values
(p = 0.15) but study 5 has a large p-value (p = 0.9). Table 1 shows the
resulting p-values from five meta-analysis methods that are derived from
classical parametric inference in Section 1. Comparing Fisher and minP in
HSB , minP is sensitive to a study that has a very small p-value (see gene B)
while Fisher, as an evidence aggregation method, is more sensitive when all
or most studies are marginally statistically significant (e.g., gene A). Stouffer
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Table 1
Four hypothetical genes to compare different meta-analysis
methods and to illustrate the motivation of rOP
Gene A Gene B Gene C Gene D
Study 1 0.1 1e–20∗ 0.25 0.15
Study 2 0.1 0.9 0.25 0.15
Study 3 0.1 0.9 0.25 0.15
Study 4 0.1 0.9 0.25 0.15
Study 5 0.1 0.9 0.25 0.9
Fisher (HSB) 0.01
∗ 1e–15∗ 0.18 0.12
Stouffer (HSB) 0.002
∗ 0.03∗ 0.07 0.10
minP (HSB) 0.41 5e–20
∗ 0.76 0.56
maxP (HSA) 1e–5
∗ 0.59 0.001∗ 0.59
rOP (r= 4) (HSr) 5e–4
∗ 0.92 0.015∗ 0.002∗
∗p-values smaller than 0.05.
behaves similarly to Fisher except that it is less sensitive to the extremely
small p-value in gene B. When we turn our attention to HSA, gene C and
gene D cannot be detected by all three of the Fisher, Stouffer and minP
methods. Gene C can be detected by both maxP and rOP as expected
(p = 0.001 and 0.015, resp.). For gene D, it cannot be identified by the
maxP method (p= 0.59) but can be detected by rOP at r = 4 (p= 0.002).
Gene D gives a good motivating example that maxP may be too stringent
when many studies are combined and rOP provides additional robustness
when one or a small portion of studies are not statistically significant. In
genomic meta-analysis, genes similar to gene D are common due to the
noisy nature of high-throughput genomic experiments or when a low-quality
study is accidentally included in the meta-analysis. Although the types of
desired markers (under HSA, HSB or HSr) depend on the biological goal
of a specific application, genes A, C and D are normally desirable marker
candidates that researchers wish to detect in most situations while gene B is
not (unless study-specific markers are expected as mentioned in Section 1).
This toy example motivates the development of a robust order statistic of
rOP below.
2.2. The rOP method. Below is the algorithm for rOP when the param-
eter r is fixed. For a given gene g, without loss of generality, we ignore
the subscript g and denote by Sr = p(r), where p(r) is the rth order statis-
tic of p-values {p1, p2, . . . , pK}. Under the null hypothesis H0, Sr follows a
beta distribution with shape parameters r and K − r + 1, assuming that
the model to generate p-values under the null hypothesis is correctly spec-
ified and all studies are independent. To implement rOP, one may apply
this parametric null distribution to calculate the p-values for all genes and
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perform a Benjamini–Hochberg (BH) correction [Benjamini and Hochberg
(1995)] to control the false discovery rate (FDR) under the general depen-
dence structure. The Benjamini–Hochberg procedure can control the FDR
at the nominal level or less when the multiple comparisons are independent
or positively dependent. Although the Benjamini–Yekutieli (BY) procedure
can be applied to a more general dependence structure of the comparisons, it
is often too conservative and unnecessary [Benjamini and Yekutieli (2001)],
especially in gene expression analysis where the comparisons are more likely
to be positively dependent and the effect sizes are usually small to mod-
erate (also see Section 4.2 for simulation results). As a result, we will not
consider the BY procedure in this paper. The parametric BH approach has
the advantage of fast computation, but in many situations the parametric
beta null distribution may be violated because the assumptions to obtain
p-values from each single study are not met and the null distributions of p-
values are not uniformly distributed. When such violations of assumptions
are suspected, we alternatively recommend a conventional permutation anal-
ysis (PA) instead. Class labels of the samples in each study are randomly
permuted and the entire DE and meta-analysis procedures are followed. The
permutation is repeated for B times (B = 500 in this paper) to simulate the
null distribution and assess the p-values and q-values. The permutation anal-
ysis is used for all meta-analysis methods (including rOP, Fisher, Stouffer,
minP and maxP) in this paper unless otherwise stated.
We note that both minP and maxP are special cases of rOP, but in this
paper we mainly consider properties of rOP as a robust form of maxP (specif-
ically, K/2≤ r≤K).
2.3. Selection of r in an application. The best selection of r should de-
pend on the biological interests. Ideally, r is a tuning parameter that is
selected by the biologists based on the biological questions asked and the
experimental designs of the studies. However, in many cases, biologists may
not have a strong prior knowledge for the selection of r and data-driven
methods for estimating r may provide additional guidance in applications.
The purpose of selecting r <K is to tolerate potentially outlying studies and
noises in the data. The noises may come from experimental limitations (e.g.,
failure in probe design, erroneous gene annotation or bias from experimental
protocol) or heterogeneous patient cohorts in different studies. Another ex-
treme case may come from inappropriate inclusion of a low-quality study into
the genomic meta-analysis. Below we introduce two complementary guide-
lines to help select r for rOP. The first method comes from the adjusted
number of detected DE genes and the second is based on pathway associa-
tion (a.k.a. gene set analysis), incorporating external biological knowledge.
2.3.1. Evaluation based on the number of detected DE genes. In the first
method, we use a heuristic criterion to find the best r such that the number
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of detected DE genes is the largest. The dashed line in Figure 1(a) shows
the number of detected DE genes using different r in rOP in a brain cancer
application. The result shows a general decreasing trend in the number of
detected DE genes when r increases. However, when we randomly permute
the p-values across genes within each study, the detected number of DE genes
also shows a bias toward small r’s (dotted line). It shows that a large number
of DE genes can be detected by a small r (e.g., r= 1 or 2) simply by chance.
To eliminate this artifact, we apply a detrending method by subtracting
the dotted permuted baseline from the dashed line. The resulting adjusted
number of DE genes (solid line) is then used to seek the maximum that
correspond to the suggested r. This detrend adjustment is similar to what
was used in the GAP statistic [Tibshirani, Walther and Hastie (2001)] when
estimating the number of clusters in cluster analysis. In such a scenario,
the curve of number of clusters (on x-axis) versus sum of squared within-
cluster dispersions is used to estimate the number of clusters. The curve
always has a decreasing trend even in random data sets and the goal is
usually to find an “elbow-like” turning point. The GAP statistic permutes
the data to generate a baseline curve and subtract it from the observed
curve. The problem becomes finding the maximum point in the detrended
curve, a setting very similar to ours.
Below we describe the algorithm for the first criterion. Using the origi-
nal K studies, the number of DE genes detected by rOP using different r
(1≤ r ≤K) is first calculated as Nr [under the certain false discovery rate
threshold, e.g., FDR = 5%; see dashed line in Figure 1(a)]. We then randomly
permute p-values in each study independently and recalculate the number of
DE genes as N
(b)
r in the bth permutation. The permutation is repeated for
B times (B = 100 in this paper) and the adjusted number of detected DE
genes is defined as N ′r = Nr −
∑B
b=1N
(b)
r /B [see solid line in Figure 1(a)].
In other words, the adjusted number of DE genes is detrended so that it
is purely contributed by the consistent DE information among studies. The
parameter r is selected so that N ′r is maximized (or we manually select r as
large as possible when N ′r reaches among the largest).
Remark 1. Note that N ′r could sometimes be negative. This happens
mostly when the signal in a single study is strong and r is small. However,
since we usually apply rOP for relatively large K and r, the negative value
is usually not an issue. We also note that, unlike the GAP statistic, the cri-
terion to choose r with the maximal adjusted number of detected DE genes
is heuristic and has no theoretical guarantee. In simulations and real appli-
cations to be shown later, this method performs well and provides results
consistent with the second criterion described below.
2.3.2. Evaluation based on biological association. Pathway analysis (a.k.a.
gene set analysis) is a statistical tool to infer the correlation of differential ex-
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Fig. 1. Results of brain cancer data set applying rOP. (a) Adjusted and unadjusted num-
ber of detected DE genes using different r. (b) Boxplots of − log(p) for the biological as-
sociation evaluation. p-values for Wilcoxon signed-rank tests are shown on the top. Black
filled rectangles represent a p-value smaller than 0.05. (c) Heatmap to show effective stud-
ies of rOP in each gene. Effective studies are shown in black and noneffective ones are in
light gray.
pression evidence in the data with pathway knowledge (usually sets of genes
with known common biological function or interactions) from established
databases. In this approach, we hypothesize that the best selection of r will
produce a DE analysis result that generates the strongest statistical associ-
ation with “important” (i.e., disease-related) pathways. Such pathways can
be provided by biologists or obtained from pathway databases. However, it
is well recognized that our understanding of biological and disease-related
pathways are relatively poor and subject to change every few years. This is
especially true for many complex diseases, such as cancers, psychiatric dis-
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orders and diabetes. In this case, it is more practical to use computational
methods to generate “pseudo” disease-related pathways that are further re-
viewed by biologists before being utilized to estimate r. Below, we develop
a computational procedure for selecting disease-related pathways. We per-
form pathway analysis using a large pathway database (e.g., GO, KEGG or
BioCarta) and select pathways that are top ranked by aggregated committee
decision of different r from rOP. The detailed algorithm is as follows:
Step I. Identification of disease-related pathways (committee decision
by [K/2] + 1≤ r≤K):
1. Apply rOP method to combine studies and generate p-values for each
gene. Run through different r, [K/2] + 1≤ r ≤K.
2. For a given pathway m, apply Kolmogorov–Smirnov test to compare the
p-values of genes in the pathway and those outside the pathway. The
pathway enrichment p-values are generated as pr,m. Its rank among all
pathways for a given r is calculated as Rr,m = rankm(pr,m). Small ranks
suggest strong pathway enrichment for pathway m.
3. The sums of ranks of different r are calculated as Sm =
∑K
r=[K/2]+1Rr,m.
The top U = 100 pathways with the smallest Sm scores are selected and
denoted as M . We treat M as the “pseudo” disease-related pathway set.
Step II. Sequential testing of improved pathway enrichment signifi-
cance:
1. We perform sequential hypothesis testing that starts from r′ =K since
conceptually we would like to pick r as large as possible. We first perform
a Wilcoxon signed-rank test to test for difference of pathway enrichment
significance for r′ =K and r′ =K− 1. In other words, we perform a two-
sample test on the paired vectors of (pK,m;m ∈M) and (pK−1,m;m ∈M)
and record the p-value as p˜K,K−1.
2. If the test is rejected (using the conventional type I error of 0.05), it
indicates that reducing from r = K to r = K − 1 can generate a DE
gene list that produce more significant pathway enrichment in M . We
will continue to reduce r′ by one (i.e., r′ = K − 1) and repeat the test
between (pr′,m;m ∈M) and (pr′−1,m;m ∈M). Similarly, the resulting p-
values are recorded as p˜r′,r′−1. The procedure is repeated until the test
from r′ is not rejected. The final r′ is selected for rOP.
Remark 2. Note that for simplicity and since this evaluation should be
examined together with the first criterion in Section 2.3.1, we will not per-
form p-value correction for multiple comparison or sequentially dependent
hypothesis testings here. Practically, we suggest to select r based on the di-
agnostic plots of the two criteria simultaneously. Examples of the selection
will be shown in Section 3.
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Remark 3. We have tested different U in real applications. As can be
expected, the selection of U did not affect the result much. In supplement
Figure 7 [Song and Tseng (2014d)], we show that the ranks for rOP with
different selection of r as well as other methods become stable enough when
U = 100 for all our applications.
2.4. One-sided test modification to avoid discordant effect sizes. Meth-
ods combining effect sizes (e.g., random or fixed effects models) are suit-
able to combine studies with binary outcome, in which case the effect sizes
are well defined as the standardized mean differences or odds ratios. Meth-
ods combining p-values, however, have advantages in combining studies
with nonbinary outcomes (e.g., multi-class, continuous or censored data),
in which case the F-test, simple linear regression or the Cox proportional
hazard model can be used to generate p-values for integration. On the other
hand, p-value combination methods usually combine two-sided p-values in
binary outcome data. A gene may be found statistically significant with up-
regulation in one study and down-regulation in another study. Such a con-
fusing discordance, although sometimes a reflection of the biological truth,
is often undesirable in most applications. Therefore, we make a one-sided
test modification to the rOP method similar to the modification that Owen
(2009) and Pearson (1934) applied on Fisher’s method. The modified rOP
statistic is defined as the minimum of the two rOP statistics combining the
one-sided tests of both tails. Details of this test statistic can be found in the
supplementary material [Song and Tseng (2014a)].
3. Applications. We applied rOP as well as other meta-analysis methods
to three microarray meta-analysis applications with different strengths of DE
signal and different degrees of heterogeneity. Supplement Table 1A–C [Song
and Tseng (2014c)] list the detailed information on seven brain cancer stud-
ies, nine major depressive disorder (MDD) studies and 16 diabetes studies
for meta-analysis. Data were preprocessed and normalized by standard pro-
cedures in each array platform. Affymetrix data sets were processed by the
RMA method and Illumina data sets were processed by manufacturer’s soft-
ware with quantile normalization for probe analysis. Probes were matched
to the same gene symbols. When multiple probes (or probe sets) matched
to one gene symbol, the probe that contained the largest variability (i.e.,
inter-quartile range) was used to represent the gene. After gene matching
and filtering, 5836, 7577 and 6645 genes remained in the brain cancer, MDD
and diabetes data sets, respectively. The brain cancer studies were collected
from the GEO database. The MDD studies were obtained from Dr. Etienne
Sibille’s lab. A random intercept model adjusted for potential confounders
was applied to each MDD study to obtain p-values [Wang et al. (2012a)].
Preprocessed data of 16 diabetes studies described by Park et al. (2009) were
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obtained from the authors. For studies with multiple groups, we followed the
procedure of Park et al. by taking the minimum p-value of all the pairwise
comparisons and adjusted for multiple tests. All the pathways used in this
paper were downloaded from the Molecular Signatures Database [MSigDB,
Subramanian et al. (2005)]. Pathway collections c2, c3 and c5 were used for
the r selection purpose.
3.1. Application of rOP. In all three applications, we demonstrate the
estimation of r for rOP using the two evaluation criteria in Section 2.3.
In the first data set, two important subtypes of brain tumors—anaplastic
astrocytoma (AA) and glioblastoma multiforme (GBM)—were compared in
seven microarray studies. To estimate an adequate r for the rOP application,
we calculated the unadjusted number, the baseline number from permuta-
tion and the adjusted number of detected DE genes using 1 ≤ r ≤ 7 under
FDR = 5% [Figure 1(a)]. The result showed a peak at r= 5. For the second
estimation method by pathway analysis, boxplots of − log10(p) (p-values cal-
culated from association of DE gene list with top pathways) versus r were
plotted [Figure 1(b)]. The Wilcoxon signed-rank tests showed that the re-
sult from r = 6 is significantly more associated with pathways than that
from r = 7 (p = 2.7e–11) and similarly for r = 5 versus r = 6 (p = 4.4e–9).
Combining the results from Figure 1(a) and (b), we decided to choose r= 5
for this application. Figure 1(c) shows the heatmap of studies effective in
rOP (when r = 5) for each detected DE gene (a total of 1469 DE genes on
the rows and seven studies on the columns). For example, if p-values for
the seven studies are (0.13,0.11,0.03,0.001,0.4,0.7,0.15), the test statistic
for rOP is SrOP = 0.15 and the five effective studies that contribute to rOP
are indicated as (1,1,1,1,0,0,1). In the heatmap, effective studies were in-
dicated by black color and noneffective studies were in light gray. As shown
in Figure 1(c), Paugh and Yamanaka were noneffective studies in almost
all detected DE genes, suggesting that the two studies did not contribute
to the meta-analysis and may potentially be problematic studies. This find-
ing agrees with a recent MetaQC assessment result using the same seven
studies [Kang et al. (2012)]. In our application, AA and GBM patients were
compared in all seven studies. We expected to detect biomarkers that have
consistent fold-change direction across studies and the one-sided corrected
rOP method was more preferable. Supplement Figure 1 [Song and Tseng
(2014d)] showed plots similar to Figure 1 for one-sided corrected rOP. The
result similarly concluded that r = 5 was the most suitable choice for this
application.
For the second application, nine microarray studies used different areas of
post-mortem brain tissues from MDD patients and control samples (supple-
ment Table 1B [Song and Tseng (2014c)]). MDD is a complex genetic disease
with largely unknown disease mechanism and gene regulatory networks. The
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postmortem brain tissues usually result in weak signals, compared to blood
or tumor tissues, which makes meta-analysis an appealing approach. In sup-
plement Figure 2(a) [Song and Tseng (2014d)], the maximizer of adjusted
DE gene detection was at r= 6 (r= 7 or 8 is also a good choice). For supple-
ment Figure 2(b), the statistical significance improved “from r = 9 to r = 8”
(p= 5.6e–14), “from r = 8 to r= 7” (p= 8.7e–7) and “from r = 7 to r= 6”
(p= 0.045). We also obtained 98 pathways that were potentially related to
MDD from Dr. Etienne Sibille. As shown in supplement Figure 2(c), the
statistical significance improved “from r = 8 to r = 7” using the 98 expert
selected pathways. Combining the results, we decided to choose r = 7 (since
r = 6 only provided marginal improvement in both criteria and we preferred
r as large as possible) for the rOP method in this application. Supplement
Figure 2(d) showed the heatmap of effective studies in rOP. No obvious prob-
lematic study was observed. The one-sided rOP was also applied (results not
shown); good selection of r appeared to be between 5 and 7.
In the last application, 16 diabetes microarray studies were combined.
These 16 studies were very heterogeneous in terms of the organisms, tissues
and experimental design (supplement Table 1C [Song and Tseng (2014c)]).
Supplement Figure 7 [Song and Tseng (2014d)] showed diagnostic plots to
estimate r. Although the number of studies and heterogeneity across data
sets were relatively larger than the previous two examples, we could still
observe similar trends in supplement Figure 7. Specifically, for supplement
Figure 3(a), it was shown that r = 7–12 detected a higher adjusted number
of DE genes. For pathway analysis, results from r = 12 were more associ-
ated with the top pathways. As a result, we decided to use r = 12 in this
application. It was noticeable that the r selection in this diabetes example
was relatively vague compared to the previous examples. Supplement Fig-
ure 3(c) showed the heatmap of effective studies in rOP. Two to four studies
(s01, s05, s08 and s14) appeared to be candidates of problematic studies,
but the evidence was not as clear as the brain cancer example in Figure 1(c).
It should be noted that the results of supplement Figure 3 used the beta
null distribution inference and Benjamini–Hochberg correction. Permuta-
tion analysis generated a relatively unstable result (supplement Figure 4),
although it suggested a similar selection of r. This was possibly due to the
unusual ad hoc DE analysis from minimum p-values of all possible pairs of
comparisons [procedures that were used in the original paper Park et al.
(2009)].
Next, we explored the robustness of rOP by mixing a randomly chosen
MDD study into seven brain cancer studies as an outlier. The results in
supplement Figure 5 [Song and Tseng (2014d)] showed that r= 5 or 6 may
be a good choice [supplement Figure 5(a) and (b)]. We used r = 6 in rOP
for this application. Supplement Figure 5(c) interestingly showed that the
mixed MDD study, together with the Paugh and Yamanaka studies, was a
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Table 2
Number of DE genes detected by different methods under FDR= 5%
rOP
Two-sided One-sided Fisher Stouffer minP maxP VC
Brain cancer 1469 (r= 5) 1625 (r= 5) 2918 2449 2380 273 328
Overlap = 1139
MDD 617 (r= 7) 86 (r= 7) 1124 1423 0 310 0
Overlap = 48
Diabetes 636 (r= 12) Not applicable 1698 1492 1 85 0
Brain + 1 MDD 751 (r= 6) Not applicable 2081 1773 1648 132 64
potentially problematic study in the rOP meta-analysis. This result verified
our intuition that rOP is robust to outlying studies and the p-values of the
outlying studies minimally contribute to the rOP statistic.
3.2. Comparison of rOP with other meta-analysis methods. We performed
rOP using r determined from Section 3.1 in four applications (brain can-
cer, MDD, diabetes and brain cancer + 1 random MDD) and compared to
Fisher’s method, Stouffer’s method, minP, maxP and vote counting. The
vote counting method will be discussed in greater detail in Section 4.3. Two
quantitative measures were used to compare the methods. The first measure
compared the number of detected DE genes from each method as a surrogate
of sensitivity (although the true list of DE genes is unknown and sensitiv-
ity cannot be calculated). The second approach was by pathway analysis,
very similar to the method we introduced to select parameter r. However,
in order to avoid bias in top pathway selection, single study analysis results
were used as the committee to select disease-related pathways. KEGG, Bio-
Carta, Reactome and GO pathways were used in the pathway analysis. The
Wilcoxon signed-rank test was then used to test if two methods detected
DE genes with differential association with disease-related pathways.
Table 2 showed the number of detected DE genes under FDR = 5%. We
can immediately observe that Fisher and Stouffer generally detected many
more biomarkers because they targeted on HSB (genes differentially ex-
pressed in one or more studies). Although minP also targeted on HSB , it
sometimes detected extremely small numbers of DE genes in weak-signal
data such as the MDD and diabetes examples. This is reasonable because
minP has very weak power to detect consistent but weak signals across stud-
ies [e.g., p-values = (0.1,0.1, . . . ,0.1)]. The stringent maxP method detected
few numbers of DE genes in general. Vote counting detected very few genes
especially when the effect sizes were moderate (in the MDD and diabetes
examples). rOP detected more DE genes than maxP because of its relaxed
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Fig. 2. Comparison of different meta-analysis methods using pathway analysis. (a) Brain
cancer. (b) MDD. (c) Diabetes. (d) Brain cancer and 1 random MDD.
HSr hypothesis setting. It identified about 50–65% fewer DE genes than
Fisher’s and Stouffer’s methods, but guaranteed that the genes detected
were differentially expressed in the majority of the studies. We also per-
formed the one-sided corrected rOP for comparison. This method detected
similar numbers of DE genes compared to two-sided rOP, and the majority
of detected DE genes in two-sided and one-sided rOP were overlapped in the
brain cancer example. The result showed that almost all DE genes detected
by two-sided rOP had a consistent fold-change direction across studies. In
MDD, the one-sided rOP detected much fewer genes than the two-sided
method. This implied that many genes related to MDD acted differently in
different brain regions and in different cohorts.
Figure 2 showed the results of biological association from pathway analysis
that were similarly shown in Figure 1(b). The result showed that the DE gene
lists generated by Fisher and Stouffer were more associated with biological
pathways. The rOP method generally performed better than maxP and
minP and had similar biological association performance to Fisher’s and
Stouffer’s methods.
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4. Statistical properties of rOP.
4.1. Power calculation of rOP and asymptotic properties. When K stud-
ies are combined, suppose r0 of the K studies have equal nonzero effect sizes
and the rest of the (K − r0) studies have zero effect sizes. That is,
H0 : θ1 = · · ·= θK = 0,
Ha : θ1 = · · ·= θr0 = θ 6= 0, θr0+1 = · · ·= θK = 0.
For a single study, the power function given effect size θ is known as
Pr(pi ≤ α0|θ). We will derive the statistical power of rOP under this simpli-
fied hypothesis setting when r0 and r for rOP are given. Under H0, the rejec-
tion threshold for the rOP statistic is β =Bα(r,K− r+1) (the α quantile of
a beta distribution with shape parameters r and K−r+1), where the signif-
icance level of the meta-analysis is set at α. The power of rejection threshold
β under Ha is Pr(p(r) ≤ β|Ha) = Pr(
∑K
i=1 I(pi ≤ β)≥ r|Ha). By definition,
Pr(pi ≤ β|θi = 0) = β and we further denote β
′ = Pr(pi ≤ β|θi = θ). The
power calculation of interest is equivalent to finding the probabilities of
having at least r successes in K independent Bernoulli trials, among which
r0 have success probabilities β
′, and K − r0 have success probabilities β:
Pr(p(r) ≤ β|Ha) =
K∑
i=r
min(i,r0)∑
j=max(0,i−K+r0)
(
r0
j
)
β′j(1− β′)r0−j
×
(
K − r0
i− j
)
βi−j(1− β)K−r0−i+j.
Remark 4. We note that the assumption of r0 equal nonzero effect
sizes can be relaxed. When the nonzero effects are not equal, the power
calculation can be done in polynomial time using dynamic programming.
Below we demonstrate some asymptotic properties of rOP.
Theorem 4.1. Assume r0 is fixed. When the effect size θ and K are
fixed and the sample size of study k Nk →∞, Pr(p(r) ≤ β|Ha)→ 1 if r≤ r0.
When r > r0, Pr(p(r) ≤ β|Ha)→ c(r)< 1 and c(r) is a decreasing function
in r.
Proof. When Nk →∞, β
′ → 1. The theorem easily follows from the
power calculation formulae. 
Theorem 4.1 states that, asymptotically, if the parameter r in rOP is
specified less or equal to the true r0, the statistical power converges to 1
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Fig. 3. Power of rOP method when Nk →∞, K = 10. (a) r0 = 6, r = 1–10. (b) r = 6,
r0 = 0–10.
as intuitively expected. When specifying r greater than r0, the statistical
power is weakened with increasing r. Particularly, maxP will have weak
power. In contrast to Theorem 4.1, for methods designed for HSB (e.g.,
Fisher’s method, Stouffer’s method and minP), the power always converges
to 1 if Nk →∞ and r0 > 0. Figure 3(a) shows the power curve of rOP for
different r when K = 10, r0 = 6 and Nk→∞.
Lemma 4.1. Assume the parameter r used in rOP is fixed. When the ef-
fect size θ and K are fixed and the sample sizes Nk→∞, Pr(p(r) ≤ β|Ha)→
1 if r0 ≥ r. When r0 < r, Pr(p(r) ≤ β|Ha)→ c(r0) < 1 and c(r0) is an in-
creasing function in r0.
Lemma 4.1 takes a different angle from Theorem 4.1. When the parameter
r used in rOP is fixed, it asymptotically has perfect power to detect all genes
that are differentially expressed in r or more studies. It then does not have
strong power to detect genes that are differentially expressed in less than
r studies. Figure 3(b) shows a power curve of rOP for K = 10, r = 6 and
Nk →∞ (solid line). We note that the dashed line [f(r) = 0 when 0≤ r0 < 6
and f(r) = 1 when 6 ≤ r0 ≤ 10] is the ideal power curve for HSr (i.e., it
detects all genes that are differentially expressed in r or more studies but
does not detect any genes that are differentially expressed in less than r
studies). Methods like Fisher, Stouffer and minP target on HSB and their
power is always 1 asymptotically when r0 > 0. The maxP method has perfect
asymptotic power when r0 = K = 10 but has relatively weak power when
r0 < K. The rOP method lies between maxP and the methods designed
for HSB . The power of rOP for r0 ≥ 6 converges to 1, and for r0 ≤ 5, the
power is always smaller than 1 as the sample sizes in single studies go to
infinity. Although the asymptotic powers of rOP for r0 = 4 and r0 = 5 are
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not too small, we are less concerned about these genes because they are still
very likely to be important biomarkers.
4.2. Power comparison in simulated studies. To evaluate the performance
of rOP in the genomic setting, we simulated a data set using the following
procedure.
Step I. Sample 200 gene clusters, with 20 genes in each and another
6000 genes that do not belong to any cluster. Denote Cg ∈ {0,1,2, . . . ,200}
as the cluster membership of gene g, where Cg = 0 means that gene g is not
in a gene cluster.
Step II. Sample the covariance matrix Σck for genes in cluster c and in
study k, where 1≤ c≤ 200 and 1≤ k ≤ 10. First, sample Σ′ck ∼W
−1(Ψ,60),
where Ψ = 0.5I20×20 + 0.5J20×20 , W
−1 denotes the inverse Wishart distri-
bution, I is the identity matrix and J is the matrix with all the elements
equal 1. Then Σck is calculated by standardizing Σ
′
ck such that the diagonal
elements are all 1’s.
Step III. Denote gc1, . . . , gc20 as the indices for the 20 genes in cluster c,
that is, Cgcj = c, where 1≤ c≤ 200 and 1≤ j ≤ 20. Assuming the effect sizes
are all zeros, sample gene expression levels of genes in cluster c for sample n
as (X ′gc1nk, . . . ,X
′
gc20nk
)T ∼MVN (0,Σck), where 1≤ n≤ 100 and 1≤ k ≤ 10,
and sample expression level for gene g which is not in a cluster (i.e., Cg = 0)
for sample n as X ′gnk ∼N(0,1), where 1≤ n≤ 100 and 1≤ k ≤ 10.
Step IV. Sample the true number of studies that gene g is DE, tg,
from a discrete uniform distribution that takes values on 1,2, . . . ,10, for
1≤ g ≤ 1000; and set tg = 0 for 1001≤ g ≤ 10,000.
Step V. Sample δgk, which indicates whether gene g is DE in study k,
from a discrete uniform distribution that takes values on 0 or 1 and with
the constraint that
∑
k δgk = tg, where 1 ≤ g ≤ 1000 and 1 ≤ k ≤ 10. For
1001≤ g ≤ 10,000 and 1≤ k ≤ 10, set δgk = 0.
Step VI. Sample the effect size µgk uniformly from [−1,−0.5]∪ [0.5,1].
For control samples, set the expression levels as Xgnk =X
′
gnk; for case sam-
ples, set the expression levels as Ygnk = X
′
g(n+50)k + µgk · δgk, for 1 ≤ g ≤
10,000, 1≤ n≤ 50 and 1≤ k ≤ 10.
In the simulated data set, 10 studies with 10,000 genes were simulated.
Within each study, there were 50 cases and 50 controls. The first 1000 genes
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Table 3
Mean FDRs for different methods in HSr with r = 6 by simulation analysis with
correlated genes. The standard deviations of the FDRs in using 100 simulations are
shown in the parentheses
FDR1 FDR2 # of detected genes
rOP (r= 6, PA) 0.0439 (± 0.0106) 0.1818 (± 0.0179) 620.16
rOP (r= 6, BH) 0.0472 (± 0.0094) 0.2029 (± 0.0184) 617.53
rOP (r= 6, BY) 0.0043 (± 0.0031) 0.1044 (± 0.0139) 539.85
Fisher 0.0441 (± 0.0090) 0.4186 (± 0.0212) 934.91
Stouffer 0.0440 (± 0.0089) 0.3623 (± 0.0217) 858.86
minP 0.0466 (± 0.0103) 0.4567 (± 0.0207) 958.26
maxP 0.0459 (± 0.0199) 0.0729 (± 0.0251) 201.02
Vote counting 0.0000 (± 0.0000) 0.0003 (± 0.0016) 234.43
were DE in 1 to 10 studies with equal probabilities; and the rest of the 9000
genes were DE in none of the studies. We denoted tg as the true number of
studies where gene g was DE. To mimic the gene dependencies in a real gene
expression data set, within the 10,000 genes, we drew 200 gene clusters with
20 genes in each. We sampled the data such that the genes within the same
cluster were correlated. The correlation matrices for different studies and
different gene clusters were sampled from an inverse Wishart distribution.
Suppose the goal of the meta-analysis was to obtain biomarkers differentially
expressed in at least 60% (6 out of 10) of the studies (i.e., HSr with r = 6).
We performed two sample t-tests in each study and combined the p-values
using rOP with r = 6. FDR ≤ 5% was controlled using the permutation
analysis. To compare rOP with other methods in the HSr setting, we defined
two FDR criteria as follows. Note that FDR1 targets onH0 : tg = 0 and FDR2
targets on H0 : tg < r:
FDR1 =
∑
g I(tg = 0 and gene g is detected)
#{genes detected}
,
FDR2 =
∑
g I(tg < r and gene g is detected)
#{genes detected}
.
Table 3 listed the average FDR1 and FDR2 for different methods calcu-
lated using 100 simulations. We can see that although FDR1 was well con-
trolled, all the methods were anti-conservative in terms of FDR2, since the
inference of the five methods was based on H0 : tg = 0 while genes with
1 ≤ tg ≤ 5 existed and were calculated toward FDR2. To compare differ-
ent FDR control methods, we also included the results of the Benjamini–
Hochberg and Benjamini–Yekutieli procedures. According to the simulation,
the Benjamini–Hochberg procedure controlled FDR similarly to the permu-
tation test. The Benjamini–Yekutieli procedure, on the other hand, was too
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Fig. 4. Simulation results for rOP and other methods with correlated genes. (a) Number
of genes detected by difference methods. The detected genes are binned according to their
tg’s. (b) Power of different methods for genes with r0 nonzero effect sizes.
conservative that the FDR1 was controlled at about 1/10 of the nominal
FDR level. Figure 4 showed the number of detected DE genes and the sta-
tistical power of different methods for genes with tg from 1 to 10. From Fig-
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ure 4(a), we noticed that Fisher, Stouffer and minP methods detected many
genes with 1 ≤ tg ≤ 5, which violated our targeted HSr with r = 6. MaxP
detected very few genes and missed many targeted markers with 6≤ tg ≤ 9.
Only rOP generated the result most compatible with HSr (r = 6). Most
genes with 6≤ tg ≤ 10 were detected. The high FDR2 = 18.2% mostly came
from genes with 4 ≤ tg ≤ 5, genes that were very likely important markers
and were minor mistakes. Vote counting detected genes with tg ≥ 6 but was
less powerful. The relationship of vote counting and rOP will be further
discussed in Section 4.3. We also performed rOP (r = 5) and rOP (r = 7)
to compare the robustness of slightly different selections of r. Among the
620.16 DE genes (averaged over 100 simulations) detected by rOP (r = 6),
594.15 (95.8%) of them were also detected by rOP (r = 5) and 516.28 (83.3%)
of them were also detected by rOP (r = 7). The result of Figure 4(b) was
consistent with the theoretical power calculation as shown in Figure 3(b).
We also performed the simulation without correlated genes. The results
were shown in the supplement Table 2 [Song and Tseng (2014c)] and sup-
plement Figure 6 [Song and Tseng (2014d)]. We noticed that the FDRs were
controlled well in both correlated and uncorrelated cases. However, the stan-
dard deviations of FDRs with correlated genes were higher than the FDRs
with only independent genes, which indicated some instability of the FDR
control with correlated genes reported by Qiu, Yakovlev et al. (2006).
4.3. Connection with vote counting. Vote counting has been used in
many meta-analysis applications due to its simplicity, while it has been crit-
icized as being problematic and statistically inefficient. Hedges and Olkin
(1980) showed that the power of vote counting converges to 0 when many
studies of moderate effect sizes are combined (see supplement Theorem 1
[Song and Tseng (2014b)]). We, however, surprisingly found that rOP has a
close connection with vote counting, and rOP can be viewed as a generalized
vote counting with better statistical properties. There are many variations
of vote counting in the literature. One popular approach is to count the
number of studies that have p-values smaller than a prespecified threshold,
α. We define this quantity as
r= f(α) =
K∑
k=1
I{pk < α}(1)
and define its related proportion as pi =E(r)/K. The test hypothesis is{
H0 :pi = pi0,
Ha :pi > pi0,
where pi0 = 0.5 is often used in the applications. Under the null hypothesis,
r ∼ BIN (K,α) and pi = α, so the rejection region can be established. In
the vote counting procedure, α and pi0 are two preset parameters and the
inference is made on the test statistic r.
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In the rOP method, we view equation (1) from another direction. We can
easily show that if we solve equation (1) to obtain α= f−1(r), the solution
will be α ∈ [p(r), p(r+1)), and one may choose α = p(r) as the solution. In
other words, rOP presets r as a given parameter, and the inference is based
on the test statistic α= p(r).
It is widely criticized that vote counting is powerless because when the
effect sizes are moderate and the power of single studies is lower than pi0,
as K increases, the percentage of significant studies will converge to the
single study power. However, in the rOP method, because the rth quantile
is used, tests of the top r studies are combined, which helps the rejection
probability of rOP achieve 1 as K→∞. It should be noted that the major
difference between rOP and vote counting is that the test statistic α= p(r)
in rOP increases as K and r = K · c increase, which keeps information of
the r smallest p-values. On the contrary, for vote counting, α is often chosen
small and fixed when K increases. In supplement Theorem 1 [Song and
Tseng (2014b)], the power of vote counting converges to 0 as K→∞, while
the power of rOP converges to 1 asymptotically as proved in supplement
Theorem 2 [Song and Tseng (2014b)].
5. Conclusion. In this paper we proposed a general class of order statis-
tics of p-values, called rth ordered p-value (rOP), for genomic meta-analysis.
This family of statistics included the traditional maximum p-value (maxP)
and minimum p-value (minP) statistics that target on DE genes in “all stud-
ies” (HSA) or “one or more studies” (HSB). We extended HSA to a robust
form that detected DE genes “in the majority of studies” (HSr) and devel-
oped the rOP method for this purpose. The new robust hypothesis setting
has an intuitive interpretation and is more adequate in genomic applications
where unexpected noise is common in the data. We developed the algorithm
of rOP for microarray meta-analysis and proposed two methods to esti-
mate r in real applications. Under “two-class” comparisons, we proposed
a one-sided corrected form of rOP to avoid detection of discordant expres-
sion change across studies (i.e., significant up-regulation in some studies but
down-regulation in other studies). Finally, we performed power analysis and
examined asymptotic properties of rOP to demonstrate appropriateness of
rOP for HSr over existing methods such as Fisher, Stouffer, minP and maxP.
We further showed a surprising connection between vote counting and rOP
that rOP can be viewed as a generalized vote counting with better statisti-
cal property. Applications of rOP to three examples of brain cancer, major
depressive disorder (MDD) and diabetes showed better performance of rOP
over maxP in terms of detection power (number of detected markers) and
biological association by pathway analysis.
There are two major limitations of rOP. First, rOP is for HSr, but the null
and alternative hypotheses are not complementary (see Section 2.1). Thus,
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it has weaker ability to exclude markers that are differentially expressed
in “less than r” studies since the null of HSr is “differentially expressed
in none of the studies.” One solution to improve the anti-conservative infer-
ence (which is also our future work) is by Bayesian modeling of p-values with
a family of beta distributions [Erickson, Kim and Allison (2009)]. Second,
selection of r may not always be conclusive from the two methods we pro-
posed; the external pathway information may especially be prone to errors
and may not be informative to the data. But since choosing slightly different
r usually gives similar results, this is not a severe problem in most applica-
tions. We have tested a different approach by adaptively choosing the best
gene-specific r that generates the best p-value. The result is, however, not
stable and the gene-specific parameter r is hard to interpret in applications.
Although many meta-analysis methods have been proposed and applied
to microarray applications, it is still not clear which method enjoys better
performance under what condition. The selection of an adequate (or best)
method heavily depends on the biological goal (as illustrated by the hypoth-
esis settings in this paper) and the data structure. In this paper, we stated
a robust hypothesis setting (HSr) that is commonly targeted in biological
applications (i.e., identify markers statistically significant in the majority of
studies) and developed an order statistic method (rOP) as a solution. The
three applications covered “cleaner” data (brain cancer) to “noisier” data
(complex genetics in MDD and diabetes), and rOP performed well in all
three examples. We expect that the robust hypothesis setting and the order
statistic methodology will find many more applications in genomic research
and traditional univariate meta-analysis in the future.
For multiple comparison control, we propose to either apply the paramet-
ric beta null distribution to assess the p-value and perform the Benjamini–
Hochberg (BH) procedure for p-value adjustment or conduct a conventional
permutation analysis by permuting class labels in each study. The former
approach is easy to implement, and the latter approach better preserves the
gene correlation structure in the inference. Instead of the BH procedure, we
also tested the Benjamini–Yekutieli (BY) procedure which is applicable to
the general dependence structure but found that it is overly conservative
for genomic applications. The problem of FDR control under general high-
dimensional dependence structures is beyond the scope of this paper but is
critical in applications and deserves future research.
Implementation of rOP is available in the “MetaDE” package in R to-
gether with over 12 microarray meta-analysis methods in the package.
MetaDE has been integrated with other quality control methods [“MetaQC”
package, Kang et al. (2012)] and pathway enrichment analysis methods
[“MetaPath” package, Shen and Tseng (2010)]. The future plan is to in-
tegrate the three packages with other genomic meta-analysis tools into a
“MetaOmics” software suite [Wang et al. (2012b)].
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